Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) through tissue testing or clinical assessment, and whose medical team has determined that standard surgery is not suitable for them, or who have chosen not to have surgery.
- People between 18 and 85 years of age, of any gender.
- People whose tumor measures no more than 5 cm across if located toward the outer part of the lung, or no more than 3 cm across if located near the centre of the lung, and is at least 1 cm away from major blood vessels or the airway.
- People who are generally well enough to carry out light activity and self-care (as measured by a standard medical scoring tool), and who are expected to live for at least 6 months.
- People who have clear and complete medical records, including age, gender, and diagnosis details.
Who may not be able to join:
- People who have a history of any other type of cancer, or who have an autoimmune disease (a condition where the immune system attacks the body).
- Women who are pregnant or breastfeeding, or people whose lung cancer showed a negative methylation result before treatment began (confirm with trial site).
- People whose cancer has spread to the lungs from another part of the body (metastatic lung cancer).
- People who have multiple affected spots in the lung where the planned treatment would not be able to address all of them.
- People whose medical records or follow-up appointments during the study may not be able to be completed, or anyone the research team considers unsuitable for other reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yuqing Huang, Beijing Haidian Hospital
Phone: +86 13371735630
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The median lead time of SHOX2/PTGER4 methylation compared with traditional methods (tumor markers, imaging) for prediction.; Disease-free survival: Differences in DFS based on methylation status after treatment.; Dynamic concentration changes: The relative change rate of methylation levels before and after treatment and during recurrence.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.